Loading
Life sciences · Journal article
International Journal of Applied Pharmaceutics · November 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Despite the reported anticancer activities of phytocompounds such as curcumin, resveratrol, and quercetin, their clinical application remains limited. Therefore, since the invention of lipid-based nanoparticles (LBNPs), they were used to deliver low bioavailable bioactive compounds. Many types of lipid NPs emerged such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and phytosomes. Engineered LBNPs provide controlled drug release, enhance accumulation at tumor sites through passive or active targeting mechanisms. This review discusses recent advances in LBNP delivery for phytocompounds, with emphasis on preparation methods, physicochemical characterization, and application examples. This review focuses on limitations of clinical translation, including the absence of standardized formulation procedures, inconsistent reporting of critical quality attributes, insufficient long-term safety data, manufacturing challenges, and regulatory requirements. In conclusion, LBNP toxicity and biodistribution depend on formulation characteristics, dose, biological environment, and administration route, and that active targeting may improve selectivity but does not completely eliminate off-target distribution or exposure to healthy tissues.